Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis
A live, multi-source view of Tarsus Pharmaceuticals, Inc. (TARS): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease.
Sector: Healthcare · Industry: Biotechnology · United States · 370 employees · tarsusrx.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Tarsus Pharmaceuticals, Inc. (TARS) had a market capitalization of $3.98B (forward 39.0) and a beta of 0.54; the shares traded in a 52-week range of $48.20 – $91.53 (46.3% over the year).
- Market cap
- $3.98B
- Enterprise value
- $3.62B
- Forward P/E
- 39.0
- Price / book
- 11.33
- EPS (trailing)
- $-1.07
- EPS (forward)
- $2.33
- Payout ratio
- 0.0%
- 52-week range
- $48.20 – $91.53
- 52-week change
- 46.3%
- Beta
- 0.54
- Average volume
- 965,846
- Shares outstanding
- 43.9M
- Short % of float
- 14.12%
- Profit margin
- -7.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Tarsus Pharmaceuticals, Inc. (TARS) last closed at $81.12 (the last completed close before that scan).
Technicals at the scan: RSI 61 (neutral territory), price +7.3% versus its 20-day average, 20-day versus 50-day average spread +12.4%, MACD histogram 0.73.
Sentiment inputs: StockTwits 90% bullish; analyst consensus score 75/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of TARS; corporate insiders filed 0 buys and 11 sells (3 distinct filers, latest disclosure 2026-09-09). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Elizabeth Yeu Lin (0B/7S), Bobak R. Azamian (0B/3S), Seshadri Neervannan (0B/1S). Who is trading what
RapidTradeView pick record
TARS has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Tarsus Pharmaceuticals, Inc. (TARS) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell TARS.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.